<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01959243</url>
  </required_header>
  <id_info>
    <org_study_id>862</org_study_id>
    <nct_id>NCT01959243</nct_id>
  </id_info>
  <brief_title>Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025%
      versus its vehicle in a population of pediatric, adult, and geriatric subjects. At least 51%
      of subjects will be 40 years of age or older.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Overall visits to Visit 4 (Day 36)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Comparison of adverse events in the treated group vs vehicle group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drop Comfort</measure>
    <time_frame>Visit 1 (Day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured on a scale of 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alertness</measure>
    <time_frame>Visit 2 (Day 15), Visit 3 (Day 29), and Visit 4 (Day 36)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Alertness measured at 90-180 minutes after administration of the test product using a 6 point alertness scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hyperemia</condition>
  <arm_group>
    <arm_group_label>Brimonidine Tartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine tartrate ophthalmic solution 0.025%, one drop of drug into each eye, four times daily for up to four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of brimonidine tartrate ophthalmic solution, one drop of vehicle into each eye, four times daily, for up to four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate</intervention_name>
    <arm_group_label>Brimonidine Tartrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be at least 5 years of age at Visit 1 of either sex gender and any
             race or ethnicity;

          -  Have ocular health within normal limits, including a calculated best- corrected (if
             necessary) visual acuity of 0.3 logMAR or better in each eye, as measured using an
             Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.

        Exclusion Criteria:

          -  Have any ocular/systemic health problems

          -  Use of any disallowed medications during the period indicated prior to Visit 1 and
             for the duration of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quintus Ngumah, OD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris Hartman</last_name>
    <phone>585-338-5165</phone>
    <email>kris.hartman@bausch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Madison</city>
        <state>New Jersey</state>
        <zip>07940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular redness</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
